title: [New treatments of hemorrhagic rectocolitis].
abstract: The treatment of ulcerative colitis has benefited from the development of new molecules (azo-disalicylates) or new galenic forms (Pentasa, Azacol...) permitting, via oral administration, to supply the colon with 5-aminosalicylic acid without the sulfapyridine with which it was combined in salazosulfapyridine and was responsible for most side effects. Pentasa and steroids which are moderately absorbed by the colonic mucosa (tixocortol pivalate, prednisolone metasulfabenzoate may also be used un an enema form or, for some, in ointment form, to treat mild attacks in the distal forms of the disease.
mesh_terms: D000284:Administration, Oral; D000285:Administration, Rectal; D000636:Aminosalicylic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D006801:Humans; D019804:Mesalamine; D012460:Sulfasalazine / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000636:Aminosalicylic Acids; D012460:Sulfasalazine; D019804:Mesalamine; C032587:olsalazine
vernacular_title: Les traitements nouveaux de la rectocolite hémorragique.